Novo Nordisk completes acquisition of Emisphere Technologies
Novo Nordisk has completed the acquisition of Emisphere Technologies, by which it secures the full rights to the technology which has made the diabetes tablet Rybelsus possible, which the firm also plans to use in other treatments.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, Novo Nordisk completed the acquisition of Emisphere Technologies, according to a statement from the pharmaceutical giant.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk submits obesity drug for FDA approval
For subscribers
